权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Advancing Varenicline as a Treatment for Cannabis Use Disorder

推进伐尼克兰治疗大麻使用障碍

基本信息

批准号：
10004604
负责人：
Kevin M Gray
金额：
$ 98.17万
依托单位：
MEDICAL UNIVERSITY OF SOUTH CAROLINA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-15 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10004604
关键词：
Abstinence Adverse event Agonist Anterior Basic Science Cannabinoids Cannabis Clinical Trials Corpus striatum structure Cues Development Dorsal Evaluation Frequencies Individual Measures Mediating Memory Neurocognition Outcome Patient Self-Report Pharmaceutical Preparations Pharmacodynamics Pharmacotherapy Placebos Population Prefrontal Cortex Process Research Rewards Safety Short-Term Memory System Testing Thalamic structure Tobacco Use Cessation United States Urine alcohol abuse therapy alcohol use disorder base blood oxygenation level dependent response clinical effect cognitive enhancement cognitive function craving cue reactivity drug development follow-up illicit drug use improved marijuana use marijuana use disorder mesolimbic system neural circuit neuromechanism receptor research clinical testing restoration tobacco abstinence varenicline week trial

项目摘要

ABSTRACT Cannabis is the most commonly used illicit drug in the United States. Although cannabis use is widespread and basic science research on cannabinoids is well-developed, advancements in medication development for cannabis use disorder (CUD) have been limited. Varenicline, a selective nicotinic nACH receptor partial agonist of the α4β2 subtype and a full agonist of the α7 subtype, is arguably the most effective pharmacotherapy for promoting tobacco abstinence, and has also shown promise for the treatment of alcohol use disorder. Varenicline may improve cannabis use outcomes through multiple mechanisms, including interaction with the mesolimbic dopamine system, enhancement of cognitive functioning, and restoration of inhibitory control. To date, however, varenicline has not been evaluated in individuals specifically seeking treatment for CUD. In this UG3/UH3 application, we propose to rapidly yet thoroughly assess the utility of varenicline for CUD to potentially advance varenicline through the FDA's drug development approval pipeline. In the UG3 component, we will conduct a six-week, placebo-controlled proof-of-concept clinical trial of varenicline for CUD, paired with pre- and post- evaluations of cognitive functioning and neural circuitry involved in cannabis cue reactivity and inhibitory control to elucidate the pharmacodynamics of varenicline as a treatment for CUD. If milestones of the UG3 component are met, the UH3 project will be an adequately powered 12-week clinical trial with follow-up to fully assess the efficacy of varenicline in this population.

摘要